Cameron, D., Morden, J. P., Canney, P., Velikova, G., Coleman, R., Bartlett, J., Agrawal, R., Banerji, J., Bertelli, G., Bloomfield, D., Brunt, A. M., Earl, H., Ellis, P., Gaunt, C., Gillman, A., Hearfield, N., Laing, R., Murray, N., Couper, N., Stein, R. C., Verrill, M., Wardley, A., Barrett-Lee, P., Bliss, J. M., & , (n.d.). accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet oncology, 18(7), 929–945. http://access.bl.uk/ark:/81055/vdc_100046945497.0x000017